SCHEMBL1317064

SCHEMBL1317064

Cc1ccc([Si](C)(Cl)c2ccc(C)cc2C)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.41
TP53 P04637 2/20 0.41
CYP1A2 P05177 3/20 0.36
CYP2A6 P11509 2/20 0.36
ALDH1A1 P00352 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
RAPGEF4 Q8WZA2 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.32
HTT P42858 1/20 0.32
NQO2 P16083 1/20 0.32
CYP3A4 P08684 2/20 0.32
THRB P10828 1/20 0.32
ALOX15 P16050 1/20 0.32
TRPA1 O75762 1/20 0.32
ACHE P22303 2/20 0.32
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
AMY1A P0DUB6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1314725 0.86 TDP1 (0.41) TDP1TP53CYP1A2CYP2A6ALDH1A1
SCHEMBL12815650 0.86 TDP1 (0.34) TDP1TP53CYP1A2CYP2A6ALDH1A1
SCHEMBL1315309 0.84 ALDH1A1 (0.36) TDP1TP53CYP2A6ALDH1A1L3MBTL1
SCHEMBL1317920 0.83 TDP1 (0.42) TDP1TP53CYP1A2CYP2A6ALDH1A1
SCHEMBL7778417 0.83 TDP1 (0.42) TDP1TP53CYP1A2CYP2A6ALDH1A1
SCHEMBL12816389 0.81 TP53 (0.31) TDP1TP53RAPGEF4
SCHEMBL19739521 0.81 KMT2A (0.35) TP53ALDH1A1L3MBTL1KMT2AMEN1
SCHEMBL1313505 0.81 TDP1 (0.41) TDP1TP53CYP1A2CYP2A6ALDH1A1
SCHEMBL28033237 0.80 TDP1 (0.44) TDP1TP53CYP1A2CYP2A6ALDH1A1
SCHEMBL12815568 0.78 L3MBTL1 (0.31) L3MBTL1RAPGEF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163950-B2 Processes for the production of tri-organo-monoalkoxysilanes and process for the production of tri-organo-monochlorosilanes SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20110275849-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES BANNOU TADASHI 2011-11-10 US disclosed
US-8008521-B2 Processes for the production of tri-organo-monoalkoxysilanes and process for the production of tri-organo-monochlorosilanes HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 2011-08-30 US disclosed
US-20090082585-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES BANNOU TADASHI 2009-03-26 US disclosed
US-7459577-B2 Reacting a chlorosilane with grignard reagent SHIN-ETSU CHEMICAL CO., LTD. (JP) 2008-12-02 US disclosed
US-20050070730-A1 Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes SHIN-ETSU CHEMICAL CO., LTD. (JP) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275849-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES MLX, HAX1, RPS4X TDP1 3391/4885TP53 4315/4885CYP1A2 198/4885
US-20090082585-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES MLX, HAX1, RPS4X TDP1 3391/4885TP53 4315/4885CYP1A2 198/4885
US-20050070730-A1 Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes MLX, HAX1, GRIA3 TDP1 3243/4885TP53 4548/4885CYP1A2 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.